NS Pharma’s NS-089/NCNP-02 gains FDA rare paediatric disease status

10 Jul 2023
www.pharmaceutical-technology.com
Orphan DrugOligonucleotidePhase 2
NS Pharma’s NS-089/NCNP-02 gains FDA rare paediatric disease status
Preview
Source: Pharmaceutical Technology
NS Pharma’s NS-089/NCNP-02 (brogidirsen) is intended for patients with Duchenne muscular dystrophy. Credit: Jose Luis Calvo via Shutterstock.com.
The US Food and Drug Administration (FDA) has awarded rare paediatric disease (RPD) designation to NS Pharma’s investigational therapy, NS-089/NCNP-02 (brogidirsen), to treat Duchenne muscular dystrophy.
The condition is responsive to exon 44-skipping therapy.
Recommended Reports
NS Pharma’s NS-089/NCNP-02 gains FDA rare paediatric disease status
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - KVD-001 in Diabetic Macular Edema GlobalData
NS Pharma’s NS-089/NCNP-02 gains FDA rare paediatric disease status
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Triamcinolone Acetonide in Diabetic Macular Edema GlobalData
View allCompanies IntelligenceNippon Shinyaku Co LtdNS Pharma IncView all
NS-089/NCNP-02 is an antisense nucleotide discovered in collaborative research between the National Center for Psychiatry and Neurological Medicine and Nippon Shinyaku, the parent firm of NS Pharma.
The drug candidate’s clinical development comprises a Phase II clinical trial to be carried out in the US by NS Pharma and a Phase II study to be conducted by Nippon Shinyaku in Japan.
NS Pharma will provide further trial data once subject enrolment has commenced.
The regulatory agency granted RPD status for therapies that could potentially treat serious or life-threatening ailments affecting 200,000 US patients who are 18 years or younger.
Duchenne is a progressive type of muscular dystrophy seen primarily in men. It leads to gradual weakness and skeletal, cardiac and respiratory muscle loss.
In December 2022, NS Pharma received orphan drug status from the US FDA for an investigational candidate, NS-018 (ilginatinib), to treat myelofibrosis, a rare type of blood cancer.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.